WILEX and IBA report on follow up meeting with the FDA on further steps in the development of REDECTANE®
Read it in : English
The Polish Academy of Sciences Selects IBA’s Proton Therapy Technology for the Second Time
Willis-Knighton Cancer Center in Shreveport, Louisiana, to install First Ultra-Compact Proton Therapy Solution from IBA
2011 First Half Results: Strong Improvement of the Operating Cash Flow - IBA Strenghtens its Leadership in Proton Therapy
IBA’S RADIOMED SIGNS SALES REPRESENTATIVE AGREEMENT WITH FIVE ONE STAR MEDICAL FOR VISICOIL™ IN THE US AND CANADA
Read it in : English
Press Release IBA's Radiomed announces Shonin approval for Visicoil 2011
Read it in : English
IBA PROVIDES RADIATION THERAPY COMMISSIONING SERVICES FOR CAPE COD HOSPITAL
Read it in : English
RADIOMED ANNOUNCES NEW PATENT ISSUED FOR VISICOIL MARKERS
Read it in : English
IBA celebrates its 25th anniversary and adopts from today onwards its vision for 2020 of personalized medicine
WILEX and IBA report on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process
Read it in : English
IBA erhält Bauartzulassung für das Multimeter MagicMax
Read it in : German
IBA to Distribute RadCheck and BrachyCheck Software Solutions for Enhanced Quality Assurance in Radiation Therapy
Read it in : English
IBA Takes a 25 % stake in PET Net Germany and reinforces global PET radiopharmaceuticals network
IBA signs a contract with Skandionkliniken for the installation of Scandinavia first dedicated proton therapy center
2010 Annual Results - Net Income Growth - Payment of a Dividend of 15 euro cents per share - Record Order Book
IBA invests in new VisicoilTM manufacturing facility
Read it in : English
Sign up for the latest
IBA Dosimetry updates.
